BR112021020612A2 - Métodos para tratamento de sujeitos com artrite psoriática - Google Patents

Métodos para tratamento de sujeitos com artrite psoriática

Info

Publication number
BR112021020612A2
BR112021020612A2 BR112021020612A BR112021020612A BR112021020612A2 BR 112021020612 A2 BR112021020612 A2 BR 112021020612A2 BR 112021020612 A BR112021020612 A BR 112021020612A BR 112021020612 A BR112021020612 A BR 112021020612A BR 112021020612 A2 BR112021020612 A2 BR 112021020612A2
Authority
BR
Brazil
Prior art keywords
psoriatic arthritis
methods
treating subjects
subjects
treating
Prior art date
Application number
BR112021020612A
Other languages
English (en)
Portuguese (pt)
Inventor
Anil Raghavan
Mathuradas Raut Atul
Wardhaman Ganorkar Kirti
Siu-Long Yao
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112021020612(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR112021020612A2 publication Critical patent/BR112021020612A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021020612A 2019-04-15 2020-04-15 Métodos para tratamento de sujeitos com artrite psoriática BR112021020612A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
BR112021020612A2 true BR112021020612A2 (pt) 2021-12-28

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020612A BR112021020612A2 (pt) 2019-04-15 2020-04-15 Métodos para tratamento de sujeitos com artrite psoriática

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843958A (zh) * 2023-08-11 2026-04-10 信达生物医药科技(杭州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
ES2708988T3 (es) * 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
EP2331078B1 (en) * 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Also Published As

Publication number Publication date
SG11202111056YA (en) 2021-11-29
EP3956357A1 (en) 2022-02-23
WO2020212874A1 (en) 2020-10-22
IL287213A (en) 2021-12-01
US20220298233A1 (en) 2022-09-22
EP3956357A4 (en) 2023-01-04
JP7628962B2 (ja) 2025-02-12
MA55729A (fr) 2022-02-23
MX2021012652A (es) 2022-01-24
MY210310A (en) 2025-09-10
JP2025069284A (ja) 2025-04-30
CA3143604A1 (en) 2020-10-22
KR20210140780A (ko) 2021-11-23
PH12021552536A1 (en) 2022-07-04
CN113825768A (zh) 2021-12-21
AU2020259375A1 (en) 2021-10-28
JOP20210279A1 (ar) 2021-10-14
JP2022529266A (ja) 2022-06-20

Similar Documents

Publication Publication Date Title
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112021008873A8 (pt) Formulação
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
BR112021020612A2 (pt) Métodos para tratamento de sujeitos com artrite psoriática
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
BR112021013397A2 (pt) Anticorpos anti-tigit
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
CY1125536T1 (el) Συνθεσεις για τη θεραπεια της αμυλοειδωσης
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
BR112023020574A2 (pt) Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos
ECSP22056627A (es) Anticuerpos contra la integrina alfa 11 beta 1
BR112021024445A2 (pt) Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide